GTHX G1 Therapeutics Inc.

-0.17  -0%
Previous Close 37.4
Open 38.21
Price To Book 4.47
Market Cap 1,396,966,137
Shares 37,522,593
Volume 433,323
Short Ratio
Av. Daily Volume 504,776

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 preliminary OS data to be presented 2H 2019.
Triple-negative breast cancer
Phase 1/2 preliminary data due 3Q 2019.
Tagrisso and Lerociclib (G1T38)
EGFR mutation-positive non-small cell lung cancer (NSCLC)
Phase 2 additional data due at ESMO September 29, 2019 (webcast).
Trilaciclib plus Tecentriq
First-line small-cell lung cancer
Phase 1b additional data due 4Q 2019.
Lerociclib (G1T38) plus Faslodex
ER+ breast cancer
NDA filing due 2020.
Second/third-line small-cell lung cancer
Phase 2 patient-reported outcomes (PRO) presented at MASCC meeting June 21, 2019.
Small-cell lung cancer
Phase 1/2 preliminary data due at ESMO September 29, 2019 (webcast).
ER+, HER2- breast cancer

Latest News

  1. Edited Transcript of GTHX.O earnings conference call or presentation 7-Aug-19 8:30pm GMT
  2. G1 Therapeutics, Inc. (GTHX) Q2 2019 Earnings Call Transcript
  3. G1 Therapeutics Provides Second Quarter 2019 Corporate and Financial Update
  4. G1 Therapeutics to Participate in BTIG and Wedbush Healthcare Conferences in August
  5. G1 Therapeutics to Provide Second Quarter Corporate and Financial Update on August 7, 2019
  6. G1 Therapeutics Appoints Mark Avagliano as Chief Business Officer
  7. Hatteras Ventures-backed firm adds fresh round of capital
  8. Did Hedge Funds Drop The Ball On G1 Therapeutics, Inc. (GTHX) ?
  9. These 3 Biotech Stocks Skyrocketed Last Week -- Are They Buys Now?
  10. Harry Boxer’s three biotech stocks on the move include Nektar Therapeutics
  11. Why new cancer trial data is good news for a Triangle pharma
  12. Company News For Jun 19, 2019
  13. Why SunPower, Snap, and G1 Therapeutics Jumped Today
  14. What's Behind The Rally In Small-Cap Biotech G1 Therapeutics?
  15. G1 Therapeutics Announces Updated Results from Phase 2 Trial of Trilaciclib in Combination with Chemotherapy Showed Statistically Significant Improvement in Overall Survival in Women with Metastatic Triple-Negative Breast Cancer
  16. G1 Therapeutics to Present Patient-Reported Outcomes (PRO) Data on Trilaciclib At Multinational Association of Supportive Care in Cancer (MASCC) And International Society of Oral Oncology (ISCOO) 2019 Annual Meeting
  17. G1 Therapeutics Announces Updates to Board of Directors
  18. G1 Therapeutics to Present at Raymond James Life Sciences and MedTech Conference
  19. G1 Therapeutics Presents Additional Phase 2 Data on Trilaciclib in Small Cell Lung Cancer at 2019 American Society of Clinical Oncology (ASCO) Annual Meeting
  20. Edited Transcript of GTHX.O earnings conference call or presentation 9-May-19 8:30pm GMT